

MMR pathway testing and reporting terminology for MMR immunohistochemistry in endometrial carcinoma - An audit of compliance to NICE diagnostics guidance DG42 and BAGP guidance.

Dr. Vidusha Ranathunga , Dr Izhar Bagwan, Dr. Ben Haagsma.

Department of Cellular Pathology, Royal Surrey NHS Foundation Trust , Guildford, UK.



INTRODUCTION

- ✓ Screening for Lynch Syndrome is essential as endometrial carcinoma (EC) is the first malignancy in over 50% of affected cases.

OBJECTIVES

- ✓ This study evaluated compliance with NICE diagnostics guidance DG42 and assessed interpretation and reporting terminology for MMR immunohistochemistry in line with BAGP 2020 recommendations.
- ✓ Secondary objectives included determining the prevalence of MMR deficiencies and assessing concordance between pre-operative and post-operative EC diagnoses.

METHODOLOGY

- ✓ A total of 180 patients with EC managed at the Royal Surrey Hospital between January 2023 and June 2025 were included.
- ✓ Both curettage and hysterectomy specimens underwent MMR testing.

CONCLUSION

- ✓ Excellent (100%) compliance with NICE DG42 and BAGP 2020 guidance was demonstrated.
- ✓ All cases with MMR deficiency were referred for further genetic evaluation, resulting in complete (100%) referral.
- ✓ Diagnostic concordance was highest in low-grade EC, highlighting the importance of comprehensive sampling for accurate histological assessment.
- ✓ Discordance was mainly due to high-grade tumours initially sampled as polyps or identification of higher-grade areas in resection specimens.

RESULTS

Total sample size	180
Testing for Lynch syndrome done	On all 180 cases
MMR IHC done	90%, 162/180
Molecular MSI done	10% , 18/180
MMR IHC proficient	75.95%, 123/162
MLH1 and PMS 2 loss	12.96%, 21/162
MLH1 promoter region was methylated	95.23%, 20/21
MLH1 promoter region was not methylated	4.76%, 1/21
PMS2 loss	6.17%, 10/162
MSH2 and MSH6 loss	2.46%, 4/162
MSH6 loss	2.46%, 4/162
Microsatellite stable	72.22%, 13/18
Microsatellite instability high	27.77%, 5/18
MLH1 promoter region was methylated	60%, 3/5
MLH1 promoter region was not methylated.	40%, 2/5
Histological Type	Concordance (%)
Grade 1 Endometrioid Carcinoma	90.62%
Grade 2 Endometrioid Carcinoma	45.16%
Grade 3 Endometrioid Carcinoma	41.66%
Serous Carcinoma	63.15%
Clear Cell Carcinoma	40.00%
Carcinosarcoma	90.90%

Key words: MMR , Endometrial carcinoma, DG42 guideline.